It is a chronic autoimmune rheumatic disease of connective tissues.
In this disease, a protein, collagen, is formed in the excessive amount in the extracellular spaces between the connective tissues.
This results in the thickening and tightening of the skin.
Blood vessels may become thickened and function improperly that further leads to high blood pressure and tissue damage.
It is most common on the face and hands
Narrowing of the hands and feet’s blood vessels resulting in cold toes or fingers that turn red, blue, or, white (Raynaud’s phenomenon)
Systemic Scleroderma Treatment Market: IntroductionAn autoimmune disorder that affects the skin and internal organs is called systemic scleroderma.
Autoimmune diseases occur when the immune system malfunctions and destroys the body's own tissues and organs.In Greek, the term 'scleroderma' means rough skin, and the disorder is distinguished by the deposition of scar tissue (fibrosis) on the skin and other organs.
The esophagus, heart, lungs, and kidneys are the most frequently affected organs.Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=81482Key Drivers, Restrains, and Opportunities of Global Systemic Scleroderma Treatment MarketIncrease in prevalence of systemic scleroderma is boosting the demand for therapies used to treat the symptoms related to systemic scleroderma, thereby driving the treatment market.
For instance, the documented prevalence of systemic scleroderma in Europe and North America was 7.2–33.9 and 13.5–44.3 per 100,000 people, respectively, while the annual occurrence figures was 0.6–2.3 and 1.4–5.6 per 100,000 people.Pharmaceutical and biotechnology industries are focused on the development of new potential therapy for the treatment of systemic scleroderma, which is further driving the systemic scleroderma treatment market.
Novartis has also successfully completed Phase 2 trial of Niliotinib for the treatment of systemic sclerosis, which in turn is estimated to boost the systemic scleroderma treatment market in the near future.Request COVID Analysis on Systemic Scleroderma Treatment Market –https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=81482Exponential increase in the number of government interventions and services available to raise awareness about the condition and therapeutic alternatives is a major factor driving the development and demand for treatment of systemic sclerodermaLikewise, strong rise in understanding among the population regarding preventive healthcare is also estimated to fuel the demand during the forecast period.
The diagnosis and origin of the systemic sclerosis is still unclear, which makes it all the more difficult for doctors to choose medications for symptom relief, as each case of scleroderma is distinctive, which in turn is anticipated to hamper the market for treatment of systemic scleroderma.Request customization on Systemic Scleroderma Treatment Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR_id=81482North America to Capture Major Share of Global Systemic Scleroderma Treatment MarketNorth America is expected to account for a major share of the global systemic scleroderma treatment market due to the high prevalence of systemic scleroderma in the regionAs compared to the U.S., Europe holds a relatively minro share, primarily due to higher usage of generics and biosimilars for off-label systemic scleroderma therapy.
